Tvardi Therapeutics Appoints Sujal Shah as Chairman and Adds Shaheen Wirk to the Board of Directors March 25, 2024
Tvardi Therapeutics Announces Presentation of REVERTLIVER CANCER Phase 2 Clinical Trial Using TTI-101, A Novel STAT3 Inhibitor, at 2024 ASCO Gastrointestinal Cancers Symposium January 18, 2024
Tvardi Therapeutics to Present at the 35th Annual Piper Sandler Healthcare Conference November 21, 2023